Product Description
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.
AI Product Description
*The following content is generated by AI and is for reference only.
Talazoparib is a potent, oral small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP), specifically targeting the PARP1 and PARP2 enzymes. With the molecular formula C26H30FN7O4S and CAS Registry Number 986514-18-1, this compound represents a significant advancement in targeted cancer therapy. It functions through a mechanism known as synthetic lethality, where the inhibition of PARP enzymes prevents DNA repair in cells that already possess defects in homologous recombination repair pathways, such as those carrying BRCA1 or BRCA2 mutations. When these defective cells attempt to replicate, they accumulate lethal levels of DNA damage, leading to cell cycle arrest and apoptosis. This selective toxicity allows Talazoparib to effectively target tumor cells while sparing most healthy tissues.
Clinically, Talazoparib has been approved by regulatory agencies for the treatment of adult patients with HER2-negative metastatic breast cancer who harbor a germline BRCA mutation and have received prior endocrine-based therapy. Its high affinity for PARP enzymes, characterized by a low nanomolar IC50 value, distinguishes it from earlier generation inhibitors, often resulting in superior efficacy in preclinical models. The drug is typically administered once daily as a single tablet, offering a convenient oral dosing regimen for patients. Common adverse events associated with its use include anemia, fatigue, nausea, and thrombocytopenia, necessitating careful monitoring of blood counts during treatment. Beyond breast cancer, ongoing clinical trials are investigating its potential in other malignancies, including ovarian, prostate, pancreatic, and lung cancers, particularly in populations with homologous recombination deficiency. As precision medicine evolves, Talazoparib stands as a cornerstone therapy for genetically defined subsets of cancer patients, transforming outcomes for those with specific genetic vulnerabilities. Its development underscores the critical importance of identifying biomarkers to guide therapeutic selection in modern oncology.